Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Carlos De Andrea"'
Autor:
José L. Solórzano, Victoria Menéndez, Edwin Parra, Luisa Solis, Ruth Salazar, Mónica García-Cosío, Fina Climent, Sara Fernández, Eva Díaz, Alejandro Francisco-Cruz, Joseph Khoury, Mei Jiang, Auriole Tamegnon, Carlos Montalbán, Ignacio Melero, Ignacio Wistuba, Carlos De Andrea, Juan F. García
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The Hodgkin and Reed – Sternberg (HRS) cells in classical Hodgkin Lymphoma (cHL) actively modify the immune tumor microenvironment (TME) attracting immunosuppressive cells and expressing inhibitory molecules. A high frequency of myeloid cells in th
Externí odkaz:
https://doaj.org/article/eca23b7e29a44b36a41152a418b1a45b
Autor:
Iñaki Eguren-Santamaría, Inmaculada Rodríguez, Claudia Herrero-Martin, Eva Fernández de Piérola, Arantza Azpilikueta, Sandra Sánchez-Gregorio, Elixabet Bolaños, Gabriel Gomis, Paula Molero-Glez, Enrique Chacón, José Ángel Mínguez, Santiago Chiva, Fernando Diez-Caballero, Carlos de Andrea, Álvaro Teijeira, Miguel F. Sanmamed, Ignacio Melero
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Biomarkers for cancer immunotherapy are an unmet medical need. The group of Daniela Thommen at the NKI recently reported on novel methodologies based on short-term cultures of patient-derived tumor fragments whose cytokine concentrations in the super
Externí odkaz:
https://doaj.org/article/09779cffd119438d95ea60cb833a5d60
Autor:
Giorgia Sonzini, Sofia Granados-Aparici, Sabina Sanegre, Angel Diaz-Lagares, Juan Diaz-Martin, Carlos de Andrea, Núria Eritja, Aida Bao-Caamano, Nicolás Costa-Fraga, David García-Ros, Carmen Salguero-Aranda, Ben Davidson, Rafael López-López, Ignacio Melero, Samuel Navarro, Santiago Ramon y Cajal, Enrique de Alava, Xavier Matias-Guiu, Rosa Noguera
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 10 (2022)
The incidence of new cancer cases is expected to increase significantly in the future, posing a worldwide problem. In this regard, precision oncology and its diagnostic tools are essential for developing personalized cancer treatments. Digital pathol
Externí odkaz:
https://doaj.org/article/1debe2f1f3eb466fb9188e4c9d95f9d3
Autor:
Jose I. Echeveste, Tania Labiano, Eva Tejerina, Allan Argueta, Carlos de Andrea, Maria D. Lozano
Publikováno v:
Journal of Molecular Pathology, Vol 2, Iss 2, Pp 55-65 (2021)
In the era of personalized medicine, there is an increasing demand for comprehensive and complex diagnosis using minimally invasive techniques. Nowadays, it is mandatory to integrate biomarkers in the diagnostic process, as well as in the treatment a
Externí odkaz:
https://doaj.org/article/88db4a81396047bcad1eca5360a72796
Autor:
Juan Luis Onieva, Qingyang Xiao, Miguel-Ángel Berciano-Guerrero, Aurora Laborda-Illanes, Carlos de Andrea, Patricia Chaves, Pilar Piñeiro, Alicia Garrido-Aranda, Elena Gallego, Belén Sojo, Laura Gálvez, Rosario Chica-Parrado, Daniel Prieto, Elisabeth Pérez-Ruiz, Angela Farngren, María José Lozano, Martina Álvarez, Pedro Jiménez, Alfonso Sánchez-Muñoz, Javier Oliver, Manuel Cobo, Emilio Alba, Isabel Barragán
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 16, p 9124 (2022)
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. This limitation is exacerbate
Externí odkaz:
https://doaj.org/article/5fcf3b37b8984f97b39c6a26a3167784
Autor:
Sabina Sanegre, Núria Eritja, Carlos de Andrea, Juan Diaz-Martin, Ángel Diaz-Lagares, María Amalia Jácome, Carmen Salguero-Aranda, David García Ros, Ben Davidson, Rafel Lopez, Ignacio Melero, Samuel Navarro, Santiago Ramon y Cajal, Enrique de Alava, Xavier Matias-Guiu, Rosa Noguera
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
The invasive tumor front (the tumor–host interface) is vitally important in malignant cell progression and metastasis. Tumor cell interactions with resident and infiltrating host cells and with the surrounding extracellular matrix and secreted fact
Externí odkaz:
https://doaj.org/article/743805c8e0f34b5ba6114838c5cfc6a8
Autor:
Emilio Esteban, Francisco Exposito, Guillermo Crespo, Julio Lambea, Alvaro Pinto, Javier Puente, Jose A. Arranz, Miriam Redrado, Cristina Rodriguez-Antona, Carlos de Andrea, Marta Lopez-Brea, Esther Redin, Angel Rodriguez, Diego Serrano, Jorge Garcia, Enrique Grande, Daniel Castellano, Alfonso Calvo
Publikováno v:
Cancers, Vol 13, Iss 11, p 2849 (2021)
Sunitinib and pazopanib are standard first-line treatments for patients with metastatic renal cell carcinoma (mRCC). Nonetheless, as the number of treatment options increases, there is a need to identify biomarkers that can predict drug efficacy and
Externí odkaz:
https://doaj.org/article/eb789064de384b4eb675c9298d8cffa2
Autor:
Iosune Baraibar, Marta Roman, María Rodríguez-Remírez, Inés López, Anna Vilalta, Elisabeth Guruceaga, Margarita Ecay, María Collantes, Teresa Lozano, Diego Alignani, Ander Puyalto, Ana Oliver, Sergio Ortiz-Espinosa, Haritz Moreno, María Torregrosa, Christian Rolfo, Christian Caglevic, David García-Ros, María Villalba-Esparza, Carlos De Andrea, Silvestre Vicent, Rubén Pío, Juan José Lasarte, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo
Publikováno v:
Cancers, Vol 12, Iss 11, p 3169 (2020)
The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from PD-1/PD-L1 blockade, largely because of immunosuppression. New immunotherapy-based combinations are under inv
Externí odkaz:
https://doaj.org/article/6fde1333435241518074ff3b30c9fe69
Autor:
Alvaro Teijeira, Saray Garasa, Carlos Luri-Rey, Carlos de Andrea, Maria Gato, Carmen Molina, Tsuneyasu Kaisho, Assunta Cirella, Arantza Azpilikueta, Steffanie K. Wculek, Josune Egea, Irene Olivera, Inmaculada Rodriguez, Ana Rouzaut, Vladislav Verkhusha, Karmele Valencia, David Sancho, Pedro Berraondo, Ignacio Melero
Publikováno v:
Cancer Research. 82:4373-4385
The ability of conventional type-1 dendritic cells (cDC1) to cross-present tumor antigens to CD8+ T cells is critical for the induction of antitumor cytotoxic T lymphocytes. Mice that are constitutively deficient in cDC1 cells have been reported to f
Autor:
Marta M. Alonso, Ana Patiño-García, Juan Fueyo, Candelaria Gomez-Manzano, Marcel Kool, Eric H. Raabe, Jennifer A. Chan, Renata Stripecke, Ignacio Iñigo-Marco, Jaime Gallego Perez-Larraya, Montse Puigdelloses, Virginia Laspidea, Naiara Martinez-Velez, Maria Villalba, Carlos de Andrea, Lucia Marrodan, Marta Zalacain, Eva Bandres, Elizabeth Guruceaga, Sara Labiano, Marisol Gonzalez-Huarriz, Marc Garcia-Moure
Supp Figure 4 Detection of Delta-24-RGD replication at late stages of disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33cdaae4eb5c9c79460671e7f40ca7a4
https://doi.org/10.1158/1078-0432.22480413
https://doi.org/10.1158/1078-0432.22480413